Evotec SE - Company Profile
Powered by 
All the sales intelligence you need on Evotec SE in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Evotec SE fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Evotec SE.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Evotec SE (Evotec) is a drug discovery and development partnership company. It discovers and develops small molecule drugs spanning various conditions areas such as oncology, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides drug discovery services such as target identification and validation, sample management, hit identification, in vitro pharmacology services, integrated CMC, and proteomics services. Evotec's products and services cater to pharmaceutical and biotechnology companies, academic institutions, and other organizations involved in healthcare and life sciences. It has facilities in Abingdon and Alderley Park, the UK; Gottingen and Munich, Germany; Orth an der Donau, Austria; Branford, Princeton and Watertown, the US; Verona, Italy; and Toulouse and Lyon, France. Evotec is headquartered in Hamburg, Germany.
Headquarters
Germany
Address
Essener Bogen 7, Hamburg, Baden-Wurttemberg, 22419
Website
www.evotec.com
Telephone
49 40 560810
No of Employees
4,553
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EVT (ETR)
Revenue (2024)
$889.5M
-1.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
47.2%
(2024 vs 2023)
Market Cap*
$1.1B
Net Profit Margin (2024)
XYZ
46.6%
(2024 vs 2023)
* As of and is in US$
Evotec SE premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| Drug Discovery | JP3 |
| Target Identification and Validation | J. DISCOVERY |
| Hit Identification | J. MD |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Divestiture | In December, the company sold Just – Evotec Biologics EU to Sandoz AG. |
| 2025 | Financing Agreements | In October, the company secured a payment of US$25 million from Bristol Myers Squibb for scientific progress achieved within their strategic neuroscience partnership. |
| 2025 | Contracts/Agreements | In July, the company entered into an agreement to sell a 100% stake in Just–Evotec Biologics EU SAS to Sandoz for US$300 million. |
Competitor Comparison
| Key Parameters | Evotec SE | Merck & Co Inc | AstraZeneca Plc | Cobra Biologics Ltd | Charles River Germany GmbH & Co. KG |
|---|---|---|---|---|---|
| Headquarters | Germany | United States of America | United Kingdom | United Kingdom | Germany |
| City | Hamburg | Rahway | Cambridge | Keele | - |
| State/Province | Baden-Wurttemberg | New Jersey | Cambridgeshire | Staffordshire | - |
| No. of Employees | 4,553 | 75,000 | 96,100 | 134 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Christian Wojczewski | Chief Executive Officer | Senior Management | 2024 | 55 |
| Claire Hinshelwood | Chief Financial Officer | Senior Management | 2026 | - |
| Ingrid Muller | Chief Operating Officer | Senior Management | 2026 | - |
| Aurelie Dalbiez | Chief People Officer | Senior Management | 2024 | 49 |
| Cord Dohrmann, Ph.D. | Chief Scientific Officer | Senior Management | 2010 | 62 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer